Results 21 to 30 of about 1,846,702 (390)

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Science, 2020
Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute ...
T. Rogers, Fangzhu Zhao, Deli Huang, N. Beutler, Alison Burns, Wan-ting He, Oliver Limbo, C. Smith, G. Song, J. Woehl, Linlin Yang, R. Abbott, Sean Callaghan, Elijah Garcia, Jonathan Hurtado, M. Parren, Linghang Peng, S. Ramirez, James Ricketts, M. Ricciardi, Stephen A. Rawlings, N. Wu, M. Yuan, Davey M. Smith, D. Nemazee, J. Teijaro, J. Voss, I. Wilson, R. Andrabi, Bryan S. Briney, E. Landais, D. Sok, J. Jardine, D. Burton   +33 more
semanticscholar   +1 more source

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

Nature reviews. Immunology, 2022
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its ...
B. Haynes, K. Wiehe, P. Borrow, K. Saunders, Bette Korber, K. Wagh, A. McMichael, G. Kelsoe, B. Hahn, F. Alt, G. Shaw   +10 more
semanticscholar   +1 more source

HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model

Frontiers in Immunology, 2021
Recent studies showed that immunological tolerance may restrict the development of Env-specific autoreactive broadly neutralizing antibodies. This evidence is consistent with the finding that Env immunization of a systemic lupus erythematosus (SLE ...
Gabriel Siracusano, Annamaria Finardi, Claudia Pastori, Vittorio Martinelli, Roberto Furlan, Lucia Lopalco   +5 more
doaj   +1 more source

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Science, 2020
An antibody defense against COVID-19 One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat ...
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Z. Li, Shihua Li, Y. Bi, Yang Yang, Y. Gong, Haixia Xiao, Z. Fan, Shuguang Tan, Guizhen Wu, W. Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, J. Qi, G. Gao, F. Gao, Lei Liu   +24 more
semanticscholar   +1 more source

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

bioRxiv, 2021
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide.
Kai Wu, Anne P. Werner, Juan I. Moliva, M. Koch, A. Choi, Guillaume B. E. Stewart-Jones, H. Bennett, Seyhan Boyoglu-Barnum, W. Shi, B. Graham, A. Carfi, Kizzmekia S. Corbett, R. Seder, D. Edwards   +13 more
semanticscholar   +1 more source

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, Edith E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Science, 2021
Boosterism could save lives Postinfection immune protection against severe acute respiratory syndrome coronavirus 2 reinfection is not fully understood.
L. Stamatatos, Julie L. Czartoski, Yu-Hsin Wan, Leah J. Homad, Vanessa Rubin, Hayley Glantz, M. Neradilek, Emilie Seydoux, Madeleine F. Jennewein, Anna J. MacCamy, Junli Feng, G. Mize, S. D. De Rosa, A. Finzi, Maria P. Lemos, Kristen W. Cohen, Z. Moodie, M. McElrath, A. McGuire   +18 more
semanticscholar   +1 more source

Broadly neutralizing antibodies target the coronavirus fusion peptide

bioRxiv, 2022
The potential for future coronavirus outbreaks highlights the need to develop strategies and tools to broadly target this group of pathogens. Here, using an epitope-agnostic approach, we identified six monoclonal antibodies that bound to spike proteins ...
Cherrelle Dacon, C. Tucker, Linghang Peng, C. D. Lee, Ting-Hui Lin, M. Yuan, Yu Cong, Lingshu Wang, Lauren Purser, Jazmean K. Williams, C. Pyo, I. Košík, Zhe Hu, Ming Zhao, Divya Mohan, Andrew J. R. Cooper, M. Peterson, J. Skinner, S. Dixit, Erin Kollins, Louis Huzella, Donna L. Perry, R. Byrum, Sanae Lembirik, Yi Zhang, E. Yang, Man Chen, K. Leung, R. Weinberg, A. Pegu, D. Geraghty, E. Davidson, I. Douagi, S. Moir, J. Yewdell, C. Schmaljohn, Peter D. Crompton, M. Holbrook, D. Nemazee, J. Mascola, I. Wilson, Joshua Tan   +41 more
semanticscholar   +1 more source

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. [PDF]

PLoS Pathogens, 2017
Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero.
Anna Bootz, Astrid Karbach, Johannes Spindler, Barbara Kropff, Nina Reuter, Heinrich Sticht, Thomas H Winkler, William J Britt, Michael Mach   +8 more
doaj   +1 more source

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Science, 2020
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al.
A. Wajnberg, F. Amanat, A. Firpo, D. Altman, M. Bailey, M. Mansour, Meagan McMahon, Philip Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, Shirin Strohmeier, V. Simon, J. Aberg, D. Reich, F. Krammer, C. Cordon-Cardo   +17 more
semanticscholar   +1 more source